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Recent genome-wide association studies suggest that genetic factors contribute to primary biliary cirrhosis (PBC) susceptibility.
Although several reports have demonstrated that the interleukin (IL) 12 signaling pathway is involved in PBC pathogenesis, its
precise genetic factors have not been fully clarified. Here, we performed an association analysis between IL12A, IL12RB, and signal
transducer and activator of transcription 4 (STAT4) genetic variations and susceptibility to PBC. Single nucleotide polymorphisms
(SNPs) were genotyped in 395 PBC patients and 458 healthy subjects of Japanese ethnicity and evaluated for associations with
PBC susceptibility, anti-nuclear antibody (ANA) status, and anti-mitochondrial antibody (AMA) status. We detected significant
associations with PBC susceptibility for several STAT4 SNPs (rs10168266; 𝑃 = 9.4 × 10−3, rs11889341; 𝑃 = 1.2 × 10−3, rs7574865;
𝑃 = 4.0 × 10
−4, rs8179673; 𝑃 = 2.0 × 10−4, and rs10181656; 𝑃 = 4.2 × 10−5). Three risk alleles (rs7574865; 𝑃 = 0.040, rs8179673;
𝑃 = 0.032, and rs10181656; 𝑃 = 0.031) were associated with ANA status, but not with AMA positivity. Our findings confirm that
STAT4 is involved in PBC susceptibility and may play a role in ANA status in the Japanese population.
1. Introduction
Primary biliary cirrhosis (PBC) is an autoimmune liver
disease characterized by destruction of intrahepatic bile ducts
and development of hepatic fibrosis that often progress to
cirrhosis and liver failure [1]. The etiology of PBC remains
poorly understood and is considered to be complex, [2–4]
whereby a combination of inherited genetic predisposition
factors and environmental exposure is likely required for
disease development. Several genetic characteristics have
specifically been implicated in PBC etiology in the Japanese
population, including the HLA DRB1∗08 : 03-DQB1∗06 : 01
haplotype and single nucleotide polymorphisms (SNPs) in
the cytotoxic T-lymphocyte-associated protein 4 and ataxin 2-
binding protein 1 genes [5–7].
Recent genome-wide association studies (GWAS) have
identified a number of HLA and non-HLA loci with possible
relevance to the development of PBC. However, these studies
often uncovered different loci in the same signaling pathways
across ethnicities; [8–12] genetic variants of the IL12 𝛼-chain
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(IL12A) and IL12RB2 genes were associated with disease sus-
ceptibility in Caucasian studies, [8–11] but such associations
have not been confirmed in the Japanese [12].
Signal transducer and activator of transcription 4
(STAT4) is a transcription factor belonging to the STAT
family [13] that is required for the development of Th1
cells from naı̈ve CD4+ T cells [14] and IFN-𝛾 production
in response to IL12 [15]. Two chains of the IL12 receptor
form a heterodimer after IL12 binding and activate the
receptor-associated JAK kinases JAK2 and TYK2. STAT4 is
phosphorylated by these tyrosine kinases, homodimerizes
via its src homology 2 (SH2) domain, and then translocates
into the nucleus to activate cytokine-responsive gene
transcription [16]. While early GWAS initially showed a
weak association between STAT4 polymorphisms and PBC
susceptibility, [8–10] recent investigations have confirmed a
definite link between the two [11, 12] and have indicated that
common pathogenic pathways, such as IL12 signaling, play
an essential and nonredundant role in the development of
this disease and some of its clinical features.
Anti-mitochondrial antibody (AMA) positivity is the
serologic hallmark of PBC. AMA titers tend to be stable
over time in individual patients and do not correlate with
disease severity or rate of progression [1, 17]. Antinuclear
antibodies (ANA) are found in up to 70% of patients with
PBC and are suggested to be associated with more rapid
disease progression and a poorer prognosis [18]. Positivity for
anti-gp210 and anti-centromere antibodies has been related
to PBC progression as well [19, 20]. Since the association
between genetic polymorphisms and autoantibody produc-
tion has not yet been elucidated, we investigated whether
such polymorphisms contributed to a genetic predisposition
to PBC and autoantibody production in the Japanese popu-
lation.
2. Patients and Methods
2.1. Ethics Statement. This study was approved by the ethics
committees of both participating institutions (Shinshu Uni-
versity School of Medicine, Matsumoto, Japan, and the
National Hospital Organization Nagasaki Medical Center,
Omura, Japan), and written informed consent was obtained
from all participants.The study was conducted in accordance
with the principles of the Declaration of Helsinki.
2.2. Subjects. We analyzed a total of 853 subjects (395 PBC
patients and 458 sex-matched healthy controls) enrolled at
Shinshu University Hospital, Matsumoto, Japan, and the
National Hospital Organization Nagasaki Medical Center,
Omura, Japan. As the subjects had no direct relatives of non-
Japanese ethnicity, their racial background was considered to
be uniformly Japanese. A part of this study’s participants had
been enrolled in previous genetic association studies [5–7, 12,
21–25]. In particular, 298 of 395 patients (75.4%) had been
included in an earlier GWAS from Japan and were defined
as the GWAS cohort in this analysis [12]. The remaining
97 (24.6%) patients were newly diagnosed as having PBC
and were defined as the replication cohort. Newly enrolled
Table 1: Demographic and clinical data of patients.
Characteristic 𝑛 = 395
Median age, years (range) 58 (28–87)
Female/male 338/57
Autoantibody
AMA-positive, 𝑛 (%) 369 (93.4)
ANA-positive, 𝑛 (%) 271 (67.6)
Cenp positive, 𝑛 (%) 119/362 (32.9)∗
gp210 positive, 𝑛 (%) 80/260 (30.8)∗
AMA: anti-mitochondrial antibody; ANA: anti-nuclear antibody; Cenp:
anti-centromere antibody; gp210: gp210 antibody.
∗Only patients who were assessed for Cenp and gp210 are reported.
control subjects were volunteers from hospital staff who had
indicated the absence of any major illnesses in a standard
questionnaire and whose racial background was considered
to be uniformly Japanese. The sex-matched control group
consisted of 384 women and 74 men with no direct familial
relations.
The diagnosis of PBC was determined based on criteria
from the American Association for the Study of Liver Dis-
eases [26]. Serum AMA, which is specific for the pyruvate
dehydrogenase complex-E2 component, was measured by
the enzyme-linked immunosorbent assay (ELISA). An index
of greater than 7 was considered to be a positive result.
Serum ANA was determined by immunofluorescence using
HEp-2 cells, whereby a titer of ≥40 was considered to
be positive, as reported previously [27]. Patterns of ANA
reactivity were recorded as well. Serum anti-centromere
antibody was detected using commercially available ELISA
kits (MBL, Nagoya, Japan), for which an index of >5U/mL
was considered to be positive. Serum gp-210 antibody was
also measured by ELISA, whereby an index of >10 U/mL was
considered to be a positive result, as previously described [19].
All patients were negative for hepatitis B surface antigen and
antibodies to the hepatitis C and human immunodeficiency
viruses.
2.3. IL-12 Signaling-Related SNP Genotyping. Genomic DNA
from patients was isolated by phenolic extraction of sodium
dodecyl sulfate-lyzed and proteinase K-treated cells, as de-
scribed previously [28], and adjusted to a concentration of
10–15 ng/𝜇L.
IL12A (rs574808), IL12RB (rs3790567), and STAT4
(rs7574865) SNPs were selected based on reported PBC
susceptibility [8–12]. Since the STAT4 (rs7574865) SNP was
found to be significantly associated with PBC, we genotyped
an additional 7 SNPs located in this gene (rs10168266,
rs7594501, rs16833239, rs11889341, rs8179673, rs10181656, and
rs6752770) that were not evaluated in the earlier Japanese
GWAS using an SNP Genotyping Kit (Applied Biosystems,
Tokyo, Japan). These SNPs were selected based on previous
reports [8–12, 29–31]. Polymerase chain reaction (PCR)
was performed with TaqMan Assays (7500 Real Time PCR
System; Applied Biosystems, Foster City, California, USA)
following the manufacturer’s instructions.
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Table 2: IL12A, IL12RB, and STAT4 SNPs in PBC patients and healthy subjects.
Gene db SNP
Allele GWAS cohort Replication cohort Combined cohort
minor/major patients (%) patients (%) patients (%) Controls (%) P OR 95% CI
(𝑛 = 302) (𝑛 = 93) (𝑛 = 395) (𝑛 = 458)
IL12A rs574808 C/T 17.2 18.3 17.5 18.1 0.75
IL12RB rs3790567 A/G 26.8 22.0 25.7 22.9 0.18
STAT4 rs7574865 T/G 40.6 46.8 41.9 33.5 4.0 × 10−4 1.43 1.17–1.74
IL12: interleukin 12; STAT4: signal transducer activator transcription 4; PBC: primary biliary cirrhosis; SNP: single nucleotide polymorphism; OR: odds ratio;
CI: confidence interval.
Table 3: STAT4 SNPs in PBC patients and healthy subjects.
db SNP Allele minor/major Patients (%) (𝑛 = 395) Controls (%) (𝑛 = 458) P 𝑃
𝑐
OR 95% CI
rs10168266 A/G 34.5 28.7 9.4 × 10−3 0.038 1.31 1.07–1.61
rs7594501 A/G 12.7 16.7 0.021
rs16833239 T/C 13.0 16.4 0.046
rs11889341 T/C 39.1 31.7 1.2 × 10−3 9.6 × 10−3 1.39 1.14–1.69
rs7574865 T/G 41.9 33.5 4.0 × 10−4 3.2 × 10−3 1.43 1.17–1.74
rs8179673 G/A 42.1 33.5 2.0 × 10−4 1.6 × 10−3 1.44 1.19–1.75
rs10181656 G/C 43.3 33.7 4.2 × 10−5 3.4 × 10−4 1.50 1.24–1.83
rs6752770 G/A 15.0 17.8 0.120
STAT4: signal transducer activator transcription 4; PBC: primary biliary cirrhosis; SNP: single nucleotide polymorphism; OR: odds ratio; 𝑃
𝑐
: corrected P value;
CI: confidence interval.
2.4. Statistical Analysis. All examined SNPs in control groups
were in the Hardy-Weinberg equilibrium. The R-software
“Haploview” [32] version 4.2 was used to evaluate the
haplotype structure of the 8 STAT4 SNPs. Pairwise link-
age disequilibrium (LD) patterns and haplotype frequency
analysis for all SNPs in patients and controls were assessed
by the block definition established by Gabriel et al. [33].
We assessed the significance of allele distribution between
patients and controls using the 𝜒2 test by means of 2 × 2
comparisons. A 𝑃 value of less than 0.05 was considered
to be statistically significant. We adjusted 𝑃 values using
Bonferroni’s correction by multiplying each locus by 8 (Pc).
Association strength was estimated by calculating the odds
ratio (OR) and 95% confidence interval (CI). Statistical
analysis of data was performed using SPSS 21.0 software
(IBM, Armonk, New York).
3. Results
3.1. Genotyping of IL12 Signaling-Related SNPs. To clarify the
genetic susceptibility to PBC based on previously reported
IL12 signaling, a total of 395 Japanese patients with PBC and
458 healthy Japanese controls were enrolled for an association
analysis of IL12A (rs574808), IL12RB (rs3790567), and STAT4
(rs7574865) SNPs (Table 2). Whereas the IL12A and IL12RB
SNPs were not associated with PBC, the rs7574865 SNP in
STAT4 showed a positive association with PBC susceptibility
(41.9% versus 33.5%; 𝑃 = 4.0 × 10−4, OR = 1.43, 95% CI =
1.17–1.74). To further examine its role in PBC, we selected
an additional 7 SNPs from STAT4 (rs10168266, rs7594501,
rs16833239, rs11889341, rs8179673, rs10181656, and rs6752770)
and genotyped them in all patients and controls. The minor
allele frequencies of A at rs10168266, T at rs11889341, T
at rs7574865, G at rs8179673, and G at rs10181656 were
significantly increased in PBC patients as compared with
controls (𝑃 = 9.4 × 10−3, 𝑃 = 1.2 × 10−3, 𝑃 = 4.0 × 10−4,
𝑃 = 2.0 × 10
−4, and 𝑃 = 4.0 × 10−5, resp.) (Table 3).
3.2. Distribution of STAT4 Haplotypes among PBC Patients
and Controls. We firstly defined LD blocks for the 8 SNPs
in STAT4 (Figure 1). The STAT4 region was divided into
two haplotype blocks, with substantial LD among the SNPs
in each block. To estimate haplotype frequency and analyze
haplotype association with PBC, we selected tag SNPs using
the Tagger algorithm from theHaploview program.Three tag
SNPs (rs7594501, rs16833239, and rs11889341) in block A and
3 tag SNPs (rs7574865, rs8179673, and rs10181656) in block
B were captured from pairwise measures of LD. The top 3
haplotype frequencies in both blocks are shown in Table 4.
Haplotype 2 (GCT) in block A was significantly associated
with PBC susceptibility (40.3% versus 32.2%; 𝑃 = 3.5 × 10−3,
OR 1.43, 95%CI 1.12–1.81), as was haplotype 5 (TGG) in block
B (43.3% versus 33.6%; 𝑃 = 6.0 × 10−4, OR 1.51, 95% CI 1.19–
1.91). In contrast, protective effects were seen for haplotype 4
(GAC) in block B (53.9% versus 65.4%; 𝑃 = 5.0 × 10−5, OR
0.62, 95% CI 0.49–0.78).
3.3. Associations between STAT4 SNPs, Haplotypes, and Au-
toantibodies. The PBC patients enrolled in this study were
highly positive for disease-specific autoantibodies (Table 1).
There were no significant differences with regard to ANA
positivity between 250 of 369 AMA-positive patients (67.8%)
and 21 of 26 AMA-negative patients (80.8%) (𝑃 = 0.245).
Among the 8 STAT4 SNPs, the frequencies of 3 minor alleles
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Table 4: STAT4 haplotypes in PBC patients and healthy subjects.
Block Haplotype SNPs Patients (%) Controls (%) P OR 95% CI
(𝑛∗ = 790) (𝑛∗ = 916)
A rs7594501 rs16833239 rs11889341
1 G C C 46.4 50.0 0.222
2 G C T 40.3 32.2 3.5 × 10−3 1.43 1.12–1.81
3 A T C 11.9 15.9 0.045
B rs7574865 rs8179673 rs10181656
4 G A C 53.9 65.4 5.0 × 10−5 0.62 0.49–0.78
5 T G G 43.3 33.6 6.0 × 10−4 1.51 1.19–1.91
6 G A G 2.1 0.0 3.0 × 10−4
STAT4: signal transducer activator transcription 4; PBC: primary biliary cirrhosis; SNP: single nucleotide polymorphism; OR: odds ratio; CI: confidence
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Figure 1: Linkage disequilibrium (LD) plot of 8 SNPs in STAT4 in
458 healthy subjects. Values of 𝑟2 corresponding to each SNPpair are
expressed as a percentage and shown within the respective square.
(T at rs7574865, G at rs8179673, and G at rs10181656) were
increased in ANA-positive PBC patients as compared with
ANA-negative patients (𝑃 = 0.040, 𝑃 = 0.032, and 𝑃 = 0.031,
resp.) (Table 5), but these statistical significances disappeared
after correction. Haplotype 5 (TGG) in block B was signifi-
cantly correlated with ANA (44.3% versus 36.3%; 𝑃 = 0.035,
OR 1.40, 95% CI 1.02–1.90) (Table 6). Interestingly, haplotype
5 was also significantly associated with the speckled pattern
of ANA as compared with the nonspeckled pattern (45.8%
versus 36.3%; 𝑃 = 0.029, OR 1.48, 95% CI 1.04–2.12) (data
not shown). No STAT4 SNPs or haplotypes were associated
with other autoantibody positivity or ANA pattern, such
as discrete speckled pattern, homogenous pattern, nucleolar
pattern, or peripheral pattern.
4. Discussion
In the present study, we investigated the association between
STAT4 SNPs and PBC susceptibility and its clinical signifi-
cance in the Japanese population. Our key findings were as
follows: (1) specific STAT4 polymorphisms and haplotypes
were significantly associated with PBC susceptibility or pro-
tection; (2) there were no significant genetic associations
between IL12A and IL12RB SNPs and PBC susceptibility, in
contrast to studies of Caucasians; [8–11] and (3) there was
a moderate relationship between STAT4 SNPs and ANA-
positive, but not AMA-positive, PBC patients.
STAT4 lies in the signaling pathways of several cytokines,
such as IL12, type I interferon, and IL23. This time, a
newly diagnosed PBC cohort, albeit small, replicated the
previous finding by Japanese GWAS [12] that a STAT4 SNP at
rs7574865 was associated with susceptibility to PBC. To eval-
uate the power of this study, larger association studies of other
ethnicities, includingChinese andCaucasian populations, are
required because small sample sizes may lead to false positive
or negative results. Moreover, we identified 4 additional SNPs
in STAT4 that conferred susceptibility to PBC and were
consistent with findings of GWAS of other ethnicities [11].
Haplotype analysis showed that 3 of the identified risk SNPs,
rs7574865, rs8179673, and rs10181656, were located in the
same LD block (Figure 1 and Table 4). These SNPs and
this haplotype have been linked with several autoimmune
diseases, including rheumatoid arthritis and systemic lupus
erythematosus (SLE) [29–31, 34–38]. In particular, it has
been reported that SNPs at rs7574865 are associated with
numerous other autoimmunediseases [35–38]. Aswe focused
only on STAT4 polymorphisms, we must concede that our
study is rather limited in depth and scope compared with
recent immunogenic studies [39, 40] using the Immunochip.
However, our findings support the notion that SNPs and
haplotypes in STAT4 may contribute to the development of
PBC and other autoimmune diseases.
In addition to our own, two earlier studies from Japan [12,
41] showed that IL12A and IL12RB SNPs were not associated
with PBC, which was in contrast to strong associations found
in Caucasian population studies [8–10, 42]. Similarly, GWAS





Table 5: Correlations between STAT4 SNPs and autoantibody positivity.
db SNP Allele ANA
+ (%) ANA− (%) P OR 95% CI AMA
+ (%) AMA− (%) P Cenp
+ (%) Cenp− (%) P gp210
+ (%) gp210− (%) Pminor/major (𝑛∗ = 271) (𝑛∗ = 124) (𝑛∗ = 369) (𝑛∗ = 26) (𝑛∗ = 119) (𝑛∗ = 243) (𝑛∗ = 80) (𝑛∗ = 180)
rs10168266 A/G 35.6 33.1 0.50 34.2 42.3 0.24 36.1 35.3 0.83 35.0 32.5 0.58
rs7594501 A/G 11.5 14.9 0.18 12.9 7.7 0.27 13.0 12.6 0.87 11.9 12.8 0.77
rs16833239 T/C 11.6 15.3 0.15 13.1 7.7 0.26 12.6 13.4 0.77 13.1 13.1 0.98
rs11889341 T/C 41.3 34.7 0.076 38.8 46.2 0.29 59.7 59.7 1.00 39.4 37.2 0.64
rs7574865 T/G 44.5 36.7 0.040 1.38 1.01–1.88 41.6 48.1 0.36 42.4 43.6 0.76 43.1 38.3 0.30
rs8179673 G/A 44.8 36.7 0.032 1.40 1.03–1.91 41.9 48.1 0.38 42.9 43.8 0.81 43.1 38.6 0.33
rs10181656 G/C 46.1 37.9 0.031 1.40 1.03–1.91 43.1 50.0 0.33 45.0 44.4 0.90 43.1 38.6 0.33
rs6752770 G/A 15.4 14.1 0.63 15.3 11.5 0.47 13.4 14.7 0.64 15.0 15.8 0.81
STAT4: signal transducer activator transcription 4; PBC: primary biliary cirrhosis; SNP: single nucleotide polymorphism; OR: odds ratio; CI: confidence interval; AMA: anti-mitochondrial antibody; ANA: anti-





Table 6: Correlations between STAT4 haplotypes and autoantibody positivity.
Block Haplotype SNPs ANA
+ (%) ANA− (%) P OR 95% CI AM
+ (%) AMA− (%) P Cenp
+ (%) Cenp− (%) P gp210
+ (%) gp210− (%) P(𝑛∗ = 542) (𝑛∗ = 248) (𝑛∗ = 738) (𝑛∗ = 52) (𝑛∗ = 238) (𝑛∗ = 486) (𝑛∗ = 160) (𝑛∗ = 360)
A rs7594501 rs16833239 rs11889341
1 G C C 46.7 49.6 0.45 47.7 46.2 0.83 46.6 46.1 0.89 47.5 49.2 0.73
2 G C T 41.3 34.7 0.076 38.8 46.2 0.29 40.3 40.3 1.00 39.4 37.2 0.64
3 A T C 11.1 14.5 0.17 12.5 7.7 0.31 12.6 12.3 0.92 11.9 12.2 0.91
B rs7574865 rs8179673 rs10181656 0.0
4 G A C 53.7 61.7 0.035 0.72 0.53–0.98 56.8 48.1 0.22 54.6 55.3 0.85 56.9 61.4 0.33
5 T G G 44.3 36.3 0.035 1.40 1.02–1.90 41.5 46.2 0.51 42.0 43.4 0.72 43.1 38.3 0.30
6 G A G 1.5 1.6 0.88 1.4 3.8 0.16 2.5 0.8 0.066 0.0 0.0 —
STAT4: signal transducer activator transcription 4; PBC: primary biliary cirrhosis; SNP: single nucleotide polymorphism; OR: odds ratio; CI: confidence interval; AMA: anti-mitochondrial antibody; ANA: anti-
nuclear antibody; Cenp: anti-centromere antibody; gp210: gp210 antibody; 𝑛∗: values for 𝑛∗ indicate two times the number of individuals since each person carries two haplotypes.
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loci for PBC, such as TNFSF15 and POU2AF1, which have not
been identified inGWAS of populations of European descent.
Meanwhile, Peters et al. found that liver damage severity at
clinical presentation is higher among non-Caucasians than
Caucasians for PBC [43]. Hence, although the IL12 pathway
through STAT4 plays an essential role in PBC etiology, there
is evidence of ethnic differences in genetic susceptibility loci.
PBC is also concurrent with other autoimmune diseases,
including Sjögren syndrome, [44] rheumatoid arthritis, [45]
and cutaneous scleroderma, [46] so we cannot exclude the
possibility of genetic overlap among these disorders.
Interestingly, our study showed a moderate association
between 3 STAT4 polymorphisms and 2 haplotypes with
ANA-positive PBC that was not seen for AMA (Tables 5
and 6). To understand its clinical relevance, we analyzed
this association with regard to ANA pattern and found a
significant relationship between these SNPs and the speckled
pattern of ANA, which was in agreement with a recent meta-
analysis showing that the presence of anti-ds-DNAantibodies
was associated with rs7574865 within STAT4 polymorphisms
in SLE patients. Our results did not support a relation-
ship between STAT4 SNPs and gp210 or anti-centromere
antibodies, despite these antibodies having been associated
with disease progression and prognosis in PBC patients [19].
Taken together, our data implied that STAT4 SNPs imparted
susceptibility to ANA-positive PBC, but for reasons that are
still unknown.Themechanisms by which genetic variants are
correlated with ANA positivity may be diverse and require
further study.
5. Conclusions
Our findings confirm that STAT4 SNPs and haplotypes
contribute to PBC susceptibility and may play a role in
mediating ANA status. STAT4 appears to factor strongly in
the pathogenesis of this and other autoimmune diseases and
requires continued study.
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